BioCryst Is Testing Galidesivir for COVID-19

BioCryst Pharmaceuticals (NASDAQ:BCRX) has started a clinical trial to test its antiviral medication galidesivir in patients with COVID-19. The U.S. government's National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, is funding the clinical trial.